Bevacizumab boosts risk for proteinuria in cancer tumor patients Cancer sufferers treated with the chemotherapy agent bevacizumab could be in an increased threat of severe loss of proteins from the kidney in to the urine that may result in significant kidney harm and may compromise the efficacy of tumor treatment. This conclusion is due to a study greater than 12,000 sufferers by Shenhong Wu, M.D., Ph.D., Principal Investigator, and co-workers at Stony Brook University INFIRMARY. Their results are reported in on the web June 10 in the Journal of the American Culture Nephrology . Previous analysis offers indicated that treatment with bevacizumab can result in urinary proteins leakage and kidney harm, however the overall risk linked to the drug and individual risk factors was unidentified.For all your references, sources and even more articles, please check out Dr. Mark Sircus blog page.About the writer:About the writer: Mark A. Sircus, Ac., OMD, is normally director of the International Medical Veritas Association Dr. Sircus was been trained in acupuncture and oriental medication at the Institute of Traditional Medication in Sante Fe, N.M., and at the institution of Traditional Medication of New England in Boston. He offered at the Central Open public Medical center of Pochutla in Mexico, and was awarded the name of doctor of oriental medication for his work.